Τreatment Standards and Outcomes of Patients With ER/PR Positive, HER2-negative Metastatic Breast Cancer (MBC)

Hellenic Society of Medical Oncology

Status: Unknown

Conditions: Metastatic Breast Cancer

Study type: Observational

Funder types: Other

Identifiers

NCT04247035

Metastatic Breast Cancer

Details and patient eligibility

About

• To capture the treatment patterns and clinical characteristics of patients with ER/PR positive, HER2-negative MBC in Greece

Full description

• To capture the treatment patterns and clinical characteristics of patients with ER/PR positive, HER2-negative MBC in Greece
• To evaluate the outcome of patients per treatment line (objective response, progression free survival, time to disease progression per line of therapy), overall survival
• To record adverse events per line of therapy
• To recording of the causes of treatment discontinuation per line of therapy

Enrollment: 300 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Women with histological confirmed ER/PR positive, HER2-negative MBC
• Age >18 years old
• Patients initiating first or second line therapy for ER/PR positive, HER2-negative MBC
• Adequate hematologic, renal and hepatic function
• Signed informed consent (ICF)

Exclusion criteria

• Active malignancy other than MBC
• Active infection